Tizanidine Hydrochloride Capsule
Product Images NDC 72789-506

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tizanidine Hydrochloride (NDC 72789-506). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

72789506 Label (72789506)

Label for tizanidine hydrochloride 2 mg capsules, containing 150 capsules per container. The label includes storage instructions, a warning that the capsules are not interchangeable with tizanidine tablets or Zanaflex® tablets, and mentions prescription-only status. Marketed by PD-Rx Pharmaceuticals, Inc., Oklahoma City, OK, and manufactured by Rubicon Research Private Limited, India. Barcodes, QR codes, expiration date (02/2025), lot number, and contact information are present.*

FDA Label Image

Figure 1 (Tizanidine Hydrochloride Capsules Figure 1)

A line graph showing plasma tizanidine concentration (ng/mL) over time in hours after dosing. The graph compares concentrations following 4 mg tizanidine tablets and capsules with and without food, plotting four groups with distinct symbols in the legend.*

FDA Label Image

Figure 2 (Tizanidine Hydrochloride Capsules Figure 2)

A line graph showing the improvement in Ashworth Score over time (hours post-dose) for three groups: 16 mg tizanidine, 8 mg tizanidine, and placebo. The y-axis represents improvement in Ashworth Score, ranging from 1 to -5, and the x-axis represents hours post-dose from 0 to 6 hours. The graph includes error bars for each data point.*

FDA Label Image

Figure 3 (Tizanidine Hydrochloride Capsules Figure 3)

A line chart showing improvement in Ashworth Score over time with two treatments: tizanidine (mean dose 28.8 mg) and placebo. Data points with error bars are plotted at three study time points: End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint (Last Observation Carried Forward). Tizanidine shows greater improvement compared to placebo across all time points.*

FDA Label Image

Chemical Structural Formula (Tizanidine Hydrochloride Capsules Structure)

Chemical structure diagram of tizanidine hydrochloride, showing the molecular arrangement including a chlorinated benzene ring fused to a thiazole and an imidazoline ring.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.